Replies to post #386465 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

For the WHO 5th 2021 edition (CNS Tumor Classification Scheme)
gliobastoma is only going to be used for IDH wild-type tumors there's no more IDH mutant GBM.

Wow... that is interesting! You sure do present some deep due diligence!

You likely remember LL's comment to Dr. Cobb at the Seattle Science Foundation back in December 2016:

But some of our data from our immunotherapy trials though, actually have shown immune therapy may actually be more beneficial in the, you know, mesenchymal subgroup of glioblastomas, which actually tend to be IDH1 mutation negative… the IDH1 wild-type tumors. And it possibly is because you know, potentially, these tumors do worse because they have more mutations, and they tend to be more aggressive. But with that being said, the fact that they have more mutations may actually make them more susceptible to immunotherapy because they have more targets. You know, there are mutations that the immune system can target. So I think a potential immunotherapy trial would be something to look into.

[flipper44]

Right. Thanks for the update.

[flipper44]

So that means, theoretically, idh slides, if any, that show patients with idh mutation, would not be considered statistically relevant in GBM trials, because as of 2021, according to WHO, glioblastoma no longer includes idh mutated tumors. Again, in one interview from a few years back, Dr. Liau shared that idh mutated tumors should really be labeled something other than GBM. Looks like she was right. The new WHO definition (2021) of GBM might allow/help us to understand why there was a latent emphasis at NWBO of obtaining idh tissue slides. Dr. liau would often refer idh mutation patients to other programs instead of compassionate DCVax, and as Senti’s quote of Dr. Liau suggests, Dr. Liau felt immunotherapy for GBM might work best on idh wildtype tumors, because they have more mutations to target (idh mutant tumors have less mutations, which can be confusing)

This would explain why the idh slides became an important component to analyzing data.

1. IDH mutant tumors less likely to respond to DCVax. (In theory)
2. IDH mutant tumors no longer (2021) considered GBM by WHO (Lykiri found this)
3. IDH mutant tumors unlikely to be in DCVax trial (a handful or less, imho)
4. IDH mutant tumors ironically have less mutations to target.
5. IDH mutant tumors typically have longer lived patients on average.

This is positive information for the DCVax-l trial, imho.